Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: DrugBank:EXPT01586 (
G418
)
2,237
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bartter syndrome (BS) is classified into 5 genotypes according to underlying mutant genes and BS III is caused by loss-of-function mutations in the
CLCNKB
gene encoding for basolateral ClC-Kb. BS III is the most common genotype in Korean patients with BS and W610X is the most common
CLCNKB
mutation in Korean BS III. In this study, we tested the hypothesis that the
CLCNKB
W610X mutation can be rescued in vitro using aminoglycoside antibiotics, which are known to induce translational read-through of a nonsense mutation. The
CLCNKB
cDNA was cloned into a eukaryotic expression vector and the W610X nonsense mutation was generated by site-directed mutagenesis. Cultured polarized MDCK cells were transfected with the vectors, and the read-through was induced using an aminoglycoside derivative,
G418
. Cellular expression of the target protein was monitored via immunohistochemistry. While cells transfected with the mutant
CLCNKB
failed to express ClC-Kb,
G418
treatment of the cells induced the full-length protein expression, which was localized to the basolateral plasma membranes. It is demonstrated that the W610X mutation in
CLCNKB
can be a good candidate for trial of translational read-through induction as a therapeutic modality.
...
PMID:Translational read-through of a nonsense mutation causing Bartter syndrome. 2377 44